Page URL: https://www.bionews.org.uk/page_93459

Breast cancer gene network expands as patent case starts in Australia

27 February 2012
Appeared in BioNews 646

A new genetic mutation linked to a greater risk of developing breast cancer has been shown to interact with the well-known breast cancer-causing gene BRCA1.

The gene in question produces a protein called Abraxas, which links the BRCA1 protein to a complex required for repairing damaged DNA. The mutation in the Abraxas gene affects the formation of this BRCA1 complex, and its ability to enter the nucleus and bind to sites of DNA damage. This eventually leads to genetic changes that increase the risk of developing breast cancer.

Researchers at Perelman School of Medicine at the University of Pennsylvania and Oulu University Hospital's Institute of Clinical Medicine and Biocenter in Finland found this mutation in about 2.4 percent of cases of familial breast cancer. These findings, published in Science Translational Medicine, establish Abraxas as a breast cancer-susceptibility gene.

'The present results warrant investigation of Abraxas as a new cancer susceptibility gene in other populations', write the authors. According to them, this mutation may, in time, be added to a list of approximately 14 mutations associated with breast cancer which cancer-prone families can be screened for.

In a separate study also examining the BRCA1 gene, published in the Journal of Pathology, researchers have, for the first time, mapped the genetic code of two breast cancers caused by mutations in BRCA1. They found that despite both tumours being caused by a mutated BRCA1 gene, their genetic sequences were different. This, scientists argue, raises the hopes for better diagnosis and treatments for the disease.

Meanwhile, the first court case in Australia challenging Myriad Genetics over their patent on BRCA1 has begun. Myriad Genetics gained a patent in 1994, and argue that the BRCA1 mutation is qualified as an invention because the act of removing it from the body changes it 'chemically, structurally and functionally'.

David Shavin QC defended the granting of the controversial patent on BRCA1, telling the Federal Court in Sydney: 'What's in the isolated nucleic acid (taken out of the body) is not the same thing that's in the cell, and that, I think, is the key issue'. He also stated that Myriad Genetics tested 'thousands and thousands' of people 20 years ago to locate the mutation in the genome.

In 2008 Genetic Technologies, a Melbourne company that holds the Australian rights for Myriad's BRCA1 patent, wrote to eight public laboratories to inform them of these patent rights, and insisted that Genetic Technologies should perform all future tests. However, the company later backed down.

Rebecca Gilsenan, the principal lawyer representing the patient group Cancer Voices Australia, who is pressing the court to invalidate the patent, argues that BRCA1's ability to code for particular proteins, which is the key characteristic that allows it to be used as a test, is identical inside the body and out.

The court case is expected to last around a week.

SOURCES & REFERENCES
Breast Cancer–Associated Abraxas Mutation Disrupts Nuclear Localization and DNA Damage Response Functions
Science Translational Medicine |  22 February 2012
Drug company defends gene mutation patent
The Australian |  21 February 2012
Gene work raises breast cancer hope
Press Association |  23 February 2012
New BRCA1-Associated Breast Cancer Susceptibility Gene Identified
Genetic Engineering and Biotechnology News |  23 February 2012
Researchers Spot New Gene Mutation Linked to Breast Cancer
US Health News |  22 February 2012
Study finds new member of the breast-cancer gene network
Medical Xpress |  22 February 2012
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
18 February 2013 - by Matthew Thomas 
A patent over a gene linked to hereditary breast and ovarian cancers is valid, an Australian federal court has ruled in a landmark case....
20 August 2012 - by Dr Sarah Spain 
In the latest instalment of a highly contested case, the US Federal Circuit Court of Appeals in Washington DC upheld Myriad Genetics' right to patent two genes, BRCA1 and BRCA2,which are associated with the risk of breast and ovarian cancer....
18 June 2012 - by Dr Martin Turner and Dr Ian Turner 
By exploring the legislative history and case law of patents both in Europe and the US, Oliver Mills asks why morality has become such a pervasive issue and whether European law in its current state is fit for purpose...
6 June 2012 - by Ruth Saunders 
23andMe, a personal genomics company, announced last week that it had been successfully awarded a patent for a gene variant which appears to protect against a high-risk mutation for Parkinson's disease...
23 April 2012 - by Dr Linda Wijlaars 
Breast cancer can be reclassified into ten separate 'diseases' based on its genetic characteristics, according to scientists. Analysis of the DNA and RNA from almost 2,000 tumours identified ten genetically different subtypes of breast cancer with different survival outcomes. The information could be used to better predict the outcomes of the disease, as well as offer tailored treatment to patients...
2 April 2012 - by Dr Sarah Spain 
The US Supreme Court has ordered that the two gene patents held by Myriad Genetics be sent back to the US Court of Appeals for the Federal Circuit, to be re-examined...
26 March 2012 - by Sarah Pritchard 
A genetic test could be used to spare breast cancer patients from having to undergo postoperative chemotherapy...
31 January 2012 - by Maria Botcharova 
Two breast cancer drugs, Avastin and Sutent, may inadvertently aid cancer growth, a study in mice suggests. The drugs, designed to reduce the blood supply to tumours, were found to encourage cancer stem cell growth, potentially fuelling the spread of the cancer...
23 January 2012 - by Ayesha Ahmad 
Myriad Genetics, a leading US molecular diagnostic company, has been granted exclusive rights to an analysis of the RAD51C gene. Mutations of the gene have been associated with an increased risk for hereditary breast and ovarian cancer and the company now hopes to develop a commercial test for RAD51C....
23 January 2012 - by Ruth Saunders 
Mutations in a single gene could be used to identify breast cancer tumours that can be tackled with cholesterol-lowering statins, a recent study has found. Scientists identified a link between a cholesterol-building mechanism in the body and disorganised cell growth indicative of cancer...
12 September 2011 - by Sarah Pritchard 
Researchers based in the USA and the Netherlands report study findings that may explain why women with mutations in the BRCA1 gene are more susceptible to breast and ovarian cancer...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.